MR-guided Tumour Boost (MRL-Boost)

University Health Network, Toronto

Status

Enrolling

Conditions

Prostate Cancer

Treatments

Radiation: MR-guided Radiotherapy Boost

Study type

Interventional

Funder types

Other

Identifiers

NCT05364229

21-6162

Details and patient eligibility

About

This is a single-arm feasibility study that is recruiting 40 patients with histologically-proven localized prostate cancer and MRI-defined lesion(s). Participants in this study will get MR-guided radiotherapy boost to MRI visible tumour before or after whole gland radiation. Participants will be followed-up as per standard of care schedule up to 5 years post-treatment.

Enrollment

40 estimated patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically-proven localized prostate cancer.
Low, Intermediate, and High-risk prostate cancer (ideally limited to 1 risk factor)
Low-risk: cT1-T2a, PSA <10, and Gleason score 6
Intermediate-risk: cT2b-c, PSA 10-20, and/or Gleason score 7
High-risk limited to 1 risk factor: >T2, PSA >20, or Gleason score >7
Intra-prostatic tumour(s) demonstrated on mpMRI histologically confirmed limited to =/< 1/3 total prostate volume
Planned for EBRT (+/- ADT)
ECOG 0 or 1
18 years of age or older
Ability to provide written informed consent to participate in the study

Exclusion criteria

Prior radiotherapy to pelvis
Radiological evidence of regional or distant metastases at the discretion of the treating physician.
Active ulcerative colitis or Crohn's Disease, at discretion of treating physician
Ataxia Telangectasia and SLE
Contraindications to MRI; including patients with pacemakers/implantable cardiac defibrillator, cerebral aneurysm clips, shrapnel injury
Severe claustrophobia